What is Zacks Research's Forecast for ONCY FY2026 Earnings?

Key Points

• Zacks Research projects Oncolytics' FY2026 EPS at ($0.24) per share (versus the consensus ($0.28)), and forecasts FY2027 and FY2028 EPS of ($0.23) and ($0.21), respectively.
• ONCY shares opened at $0.90 and were down 5.3%; the company has a market capitalization of about $104.5 million and reported quarterly EPS of ($0.08), missing estimates by $0.02.
• Analyst sentiment is mixed but averages to a "Moderate Buy" with an average target of $8.50, while insiders purchased ~404,282 shares recently and institutional ownership is roughly 6.8%.

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Equities research analysts at Zacks Research issued their FY2026 earnings per share estimates for Oncolytics Biotech in a research note issued to investors on Tuesday, April 7th. Zacks Research analyst D. Bautz anticipates that the company will earn ($0.24) per share for the year. The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.28) per share. Zacks Research also issued estimates for Oncolytics Biotech's FY2027 earnings at ($0.23) EPS and FY2028 earnings at ($0.21) EPS.

ONCY has been the subject of a number of other research reports. Weiss Ratings restated a "sell (e+)" rating on shares of Oncolytics Biotech in a report on Friday, March 27th. Wall Street Zen upgraded Oncolytics Biotech from a "strong sell" rating to a "hold" rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $8.50.

Oncolytics Biotech Stock Down 5.3%

ONCY opened at $0.90 on Wednesday. The stock has a fifty day moving average of $0.97 and a 200-day moving average of $1.05. The firm has a market capitalization of $104.52 million, a P/E ratio of -3.10 and a beta of 0.98. Oncolytics Biotech has a 12-month low of $0.33 and a 12-month high of $1.51.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last released its earnings results on Monday, March 30th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.02).

Institutional Trading of Oncolytics Biotech

Several hedge funds and other institutional investors have recently modified their holdings of ONCY. Scientech Research LLC purchased a new stake in shares of Oncolytics Biotech during the third quarter worth $25,000. Blair William & Co. IL purchased a new stake in shares of Oncolytics Biotech during the fourth quarter worth $28,000. Security National Bank of Sioux City Iowa IA acquired a new position in Oncolytics Biotech during the fourth quarter worth $29,000. Ground Swell Capital LLC acquired a new position in Oncolytics Biotech during the fourth quarter worth $30,000. Finally, CIBC Private Wealth Group LLC acquired a new position in Oncolytics Biotech during the fourth quarter worth $44,000. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Oncolytics Biotech

In other news, insider Andrew Aromando acquired 29,600 shares of the business's stock in a transaction that occurred on Wednesday, February 11th. The stock was acquired at an average cost of $0.86 per share, for a total transaction of $25,456.00. Following the completion of the acquisition, the insider owned 55,100 shares in the company, valued at approximately $47,386. The trade was a 116.08% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bernd R. Seizinger acquired 40,000 shares of the business's stock in a transaction that occurred on Thursday, February 12th. The shares were purchased at an average price of $0.85 per share, with a total value of $34,000.00. Following the completion of the acquisition, the director owned 566,991 shares of the company's stock, valued at $481,942.35. This represents a 7.59% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 404,282 shares of company stock valued at $363,232 in the last three months. 0.10% of the stock is currently owned by insiders.

About Oncolytics Biotech

Oncolytics Biotech Inc NASDAQ: ONCY is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company's lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.